Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Whistleblower: Abbott off-label TriCor scheme put patients at risk

This article was originally published in Scrip

Executive Summary

Abbott "trained, directed, incentivized and encouraged" its sales representatives to market TriCor (fenofibrate) for unapproved uses and to "misrepresent and withhold clinical information" about the medicine's known risks and its efficacy, a former employee is charging in a whistleblower lawsuit brought against the firm, which has been joined by the federal government and 22 states and the District of Columbia.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts